Kiyomi Mashima, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| WT1 Proteins | 2 | 2018 | 183 | 1.160 |
Why?
|
| Antilymphocyte Serum | 2 | 2021 | 492 | 1.120 |
Why?
|
| Graft vs Host Disease | 7 | 2024 | 3079 | 0.980 |
Why?
|
| Bone Marrow Cells | 2 | 2018 | 2413 | 0.730 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2018 | 1404 | 0.610 |
Why?
|
| Blast Crisis | 1 | 2018 | 102 | 0.600 |
Why?
|
| Lymphoma, Follicular | 5 | 2020 | 460 | 0.540 |
Why?
|
| Receptors, Interleukin-2 | 4 | 2019 | 565 | 0.530 |
Why?
|
| Cyclophosphamide | 3 | 2021 | 2234 | 0.530 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2021 | 5753 | 0.510 |
Why?
|
| Anemia, Aplastic | 1 | 2017 | 231 | 0.480 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2019 | 3636 | 0.470 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2017 | 527 | 0.430 |
Why?
|
| Encephalitis | 1 | 2017 | 441 | 0.420 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 1852 | 0.380 |
Why?
|
| Herpesvirus 4, Human | 1 | 2017 | 1080 | 0.370 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2017 | 617 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2023 | 11872 | 0.320 |
Why?
|
| Bone Marrow | 2 | 2018 | 2926 | 0.320 |
Why?
|
| Cytarabine | 6 | 2019 | 696 | 0.290 |
Why?
|
| Lymphoma | 4 | 2022 | 1900 | 0.290 |
Why?
|
| Gene Expression | 1 | 2018 | 7585 | 0.250 |
Why?
|
| Tumor Burden | 2 | 2021 | 1900 | 0.240 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2019 | 245 | 0.240 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2019 | 685 | 0.220 |
Why?
|
| Mice, SCID | 4 | 2024 | 2628 | 0.220 |
Why?
|
| Mice, Inbred NOD | 3 | 2024 | 1838 | 0.200 |
Why?
|
| Hematologic Neoplasms | 3 | 2019 | 1926 | 0.200 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 502 | 0.190 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2019 | 187 | 0.190 |
Why?
|
| Combined Modality Therapy | 5 | 2019 | 8540 | 0.180 |
Why?
|
| Transplantation Conditioning | 2 | 2019 | 1635 | 0.180 |
Why?
|
| T-Lymphocytes | 5 | 2024 | 10264 | 0.180 |
Why?
|
| Antiemetics | 1 | 2022 | 187 | 0.170 |
Why?
|
| Dermatan Sulfate | 1 | 2019 | 43 | 0.170 |
Why?
|
| Multiple Myeloma | 3 | 2023 | 5194 | 0.160 |
Why?
|
| Gabexate | 1 | 2018 | 12 | 0.160 |
Why?
|
| Chondroitin Sulfates | 1 | 2019 | 174 | 0.160 |
Why?
|
| Prednisolone | 1 | 2020 | 326 | 0.160 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 1434 | 0.160 |
Why?
|
| Dexamethasone | 3 | 2023 | 1962 | 0.160 |
Why?
|
| Busulfan | 1 | 2019 | 264 | 0.160 |
Why?
|
| Penicillin G | 1 | 2018 | 40 | 0.160 |
Why?
|
| Myeloablative Agonists | 1 | 2019 | 215 | 0.160 |
Why?
|
| Salvage Therapy | 3 | 2019 | 1274 | 0.160 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 1642 | 0.150 |
Why?
|
| Cerebral Arteries | 1 | 2021 | 490 | 0.150 |
Why?
|
| Mediastinal Diseases | 1 | 2019 | 91 | 0.150 |
Why?
|
| Heparitin Sulfate | 1 | 2019 | 223 | 0.150 |
Why?
|
| Disease-Free Survival | 5 | 2020 | 6850 | 0.150 |
Why?
|
| ROC Curve | 4 | 2019 | 3620 | 0.150 |
Why?
|
| Guanidines | 1 | 2018 | 194 | 0.150 |
Why?
|
| beta-Glucans | 1 | 2018 | 129 | 0.140 |
Why?
|
| Collagen Type I | 1 | 2021 | 616 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2017 | 633 | 0.140 |
Why?
|
| Viral Vaccines | 1 | 2022 | 596 | 0.140 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 258 | 0.140 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 3601 | 0.130 |
Why?
|
| Retrospective Studies | 19 | 2022 | 81635 | 0.130 |
Why?
|
| Leukocyte Count | 2 | 2017 | 1606 | 0.130 |
Why?
|
| Immunity | 1 | 2022 | 1002 | 0.130 |
Why?
|
| Middle Aged | 25 | 2021 | 223257 | 0.130 |
Why?
|
| Protease Inhibitors | 1 | 2019 | 750 | 0.130 |
Why?
|
| Prognosis | 8 | 2021 | 29948 | 0.130 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 429 | 0.120 |
Why?
|
| Hyperplasia | 1 | 2018 | 1150 | 0.120 |
Why?
|
| Chemokines | 1 | 2019 | 962 | 0.120 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2017 | 647 | 0.120 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2016 | 266 | 0.120 |
Why?
|
| Antigen-Presenting Cells | 1 | 2018 | 960 | 0.120 |
Why?
|
| Lymphocyte Activation | 3 | 2020 | 5503 | 0.110 |
Why?
|
| Osteomyelitis | 1 | 2018 | 408 | 0.110 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 384 | 0.110 |
Why?
|
| Adult | 20 | 2021 | 223307 | 0.110 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 2142 | 0.110 |
Why?
|
| Pneumococcal Infections | 1 | 2018 | 529 | 0.110 |
Why?
|
| Neutropenia | 1 | 2019 | 894 | 0.110 |
Why?
|
| Aged | 19 | 2021 | 171343 | 0.110 |
Why?
|
| Cisplatin | 1 | 2019 | 1655 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2018 | 12791 | 0.110 |
Why?
|
| Humans | 40 | 2024 | 766766 | 0.110 |
Why?
|
| Transplantation, Homologous | 2 | 2018 | 4860 | 0.100 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 1142 | 0.100 |
Why?
|
| Streptococcus pneumoniae | 1 | 2018 | 764 | 0.100 |
Why?
|
| Female | 25 | 2021 | 396520 | 0.100 |
Why?
|
| Antigen Presentation | 1 | 2018 | 1250 | 0.100 |
Why?
|
| Nitriles | 1 | 2017 | 981 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 996 | 0.100 |
Why?
|
| Quinolines | 1 | 2017 | 769 | 0.100 |
Why?
|
| Aniline Compounds | 1 | 2017 | 1079 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 1392 | 0.100 |
Why?
|
| Remission Induction | 4 | 2020 | 2413 | 0.100 |
Why?
|
| Blood Transfusion | 1 | 2018 | 1308 | 0.100 |
Why?
|
| Myeloproliferative Disorders | 1 | 2018 | 616 | 0.100 |
Why?
|
| Male | 26 | 2021 | 364142 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 1384 | 0.090 |
Why?
|
| Recurrence | 3 | 2019 | 8507 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 1814 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 1405 | 0.090 |
Why?
|
| Myeloid Cells | 1 | 2015 | 838 | 0.090 |
Why?
|
| Transplantation, Autologous | 3 | 2021 | 2127 | 0.090 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2018 | 1609 | 0.090 |
Why?
|
| Autoantibodies | 1 | 2019 | 2115 | 0.090 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2020 | 1663 | 0.080 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 59550 | 0.080 |
Why?
|
| Blood Platelets | 1 | 2020 | 2465 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2022 | 13643 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 1061 | 0.080 |
Why?
|
| Overweight | 1 | 2019 | 2446 | 0.080 |
Why?
|
| Doxorubicin | 3 | 2020 | 2229 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 6512 | 0.070 |
Why?
|
| Survival Rate | 2 | 2019 | 12825 | 0.070 |
Why?
|
| Daunorubicin | 2 | 2019 | 157 | 0.070 |
Why?
|
| Aclarubicin | 2 | 2017 | 12 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 2505 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 18330 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 1560 | 0.070 |
Why?
|
| Biopsy | 1 | 2018 | 6779 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 5536 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 2839 | 0.070 |
Why?
|
| Nausea | 2 | 2022 | 681 | 0.070 |
Why?
|
| Vincristine | 2 | 2020 | 1039 | 0.070 |
Why?
|
| Macrophages | 1 | 2021 | 5783 | 0.060 |
Why?
|
| Treatment Outcome | 11 | 2020 | 65273 | 0.060 |
Why?
|
| Thrombosis | 1 | 2019 | 2953 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2017 | 3043 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 5690 | 0.060 |
Why?
|
| Etoposide | 2 | 2016 | 638 | 0.060 |
Why?
|
| Young Adult | 7 | 2021 | 59939 | 0.060 |
Why?
|
| Adolescent | 8 | 2020 | 88904 | 0.060 |
Why?
|
| Prednisone | 2 | 2020 | 1566 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 3236 | 0.060 |
Why?
|
| Fatal Outcome | 2 | 2019 | 1838 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 15908 | 0.050 |
Why?
|
| Myeloma Proteins | 1 | 2021 | 71 | 0.050 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2022 | 117 | 0.050 |
Why?
|
| Ataxia Telangiectasia | 1 | 2022 | 107 | 0.050 |
Why?
|
| Rats, Inbred WKY | 1 | 2021 | 150 | 0.050 |
Why?
|
| Rats, Inbred SHR | 1 | 2021 | 187 | 0.050 |
Why?
|
| Hypertension | 1 | 2021 | 8616 | 0.040 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2021 | 289 | 0.040 |
Why?
|
| Hexokinase | 1 | 2020 | 125 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2022 | 735 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2020 | 116 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 7475 | 0.040 |
Why?
|
| Body Surface Area | 1 | 2020 | 206 | 0.040 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 12534 | 0.040 |
Why?
|
| Prothrombin Time | 1 | 2019 | 117 | 0.040 |
Why?
|
| Idarubicin | 1 | 2019 | 59 | 0.040 |
Why?
|
| Benzamidines | 1 | 2018 | 20 | 0.040 |
Why?
|
| Blood Component Transfusion | 1 | 2019 | 141 | 0.040 |
Why?
|
| Vomiting | 1 | 2022 | 652 | 0.040 |
Why?
|
| Tryptophan | 1 | 2020 | 484 | 0.040 |
Why?
|
| Animals | 5 | 2024 | 168930 | 0.040 |
Why?
|
| Bleomycin | 1 | 2019 | 492 | 0.040 |
Why?
|
| Vinblastine | 1 | 2019 | 482 | 0.040 |
Why?
|
| Decision Trees | 1 | 2019 | 508 | 0.040 |
Why?
|
| Kidney Tubules | 1 | 2019 | 454 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 11218 | 0.040 |
Why?
|
| Mice | 2 | 2024 | 81889 | 0.040 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2018 | 174 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2019 | 426 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2017 | 247 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2017 | 286 | 0.030 |
Why?
|
| Isoantigens | 1 | 2019 | 562 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2017 | 270 | 0.030 |
Why?
|
| Primary Myelofibrosis | 1 | 2019 | 209 | 0.030 |
Why?
|
| Nitrosourea Compounds | 1 | 2016 | 32 | 0.030 |
Why?
|
| Glycolysis | 1 | 2020 | 838 | 0.030 |
Why?
|
| Genes, myc | 1 | 2017 | 391 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2019 | 552 | 0.030 |
Why?
|
| Plasma | 1 | 2019 | 583 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2024 | 1806 | 0.030 |
Why?
|
| Markov Chains | 1 | 2019 | 974 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2017 | 451 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2016 | 148 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2019 | 893 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2018 | 957 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2019 | 344 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2019 | 10100 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 20708 | 0.030 |
Why?
|
| Steroids | 1 | 2020 | 936 | 0.030 |
Why?
|
| Autopsy | 1 | 2019 | 1011 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2017 | 292 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 2571 | 0.030 |
Why?
|
| Melphalan | 1 | 2016 | 425 | 0.030 |
Why?
|
| Japan | 1 | 2018 | 1417 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 598 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 696 | 0.030 |
Why?
|
| Time Factors | 3 | 2021 | 40149 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 810 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 15416 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 1740 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 1374 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 2730 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2022 | 2801 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 5329 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 2010 | 0.020 |
Why?
|
| Glucose | 1 | 2024 | 4340 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2017 | 1867 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2015 | 1638 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 3439 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 2391 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 2510 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3212 | 0.020 |
Why?
|
| Endoscopy | 1 | 2020 | 1854 | 0.020 |
Why?
|
| Kinetics | 1 | 2018 | 6287 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2019 | 1790 | 0.020 |
Why?
|
| Incidence | 2 | 2019 | 21525 | 0.020 |
Why?
|
| Acute Disease | 1 | 2020 | 7241 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2020 | 2976 | 0.020 |
Why?
|
| Disease Management | 1 | 2019 | 2533 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2823 | 0.020 |
Why?
|
| Propensity Score | 1 | 2016 | 1972 | 0.020 |
Why?
|
| Neutrophils | 1 | 2020 | 3782 | 0.020 |
Why?
|
| Risk Factors | 3 | 2020 | 74881 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2019 | 3464 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 5890 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 4891 | 0.020 |
Why?
|
| Rats | 1 | 2021 | 23717 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 10745 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2015 | 9661 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2018 | 4855 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2018 | 10445 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39309 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 30213 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 41710 | 0.010 |
Why?
|